51 results about "Bacillus anthrax" patented technology

An optimized synthetic polynucleotide encoding a Bacillus anthracis protective antigen and an anthrax vaccine based on the encoded protective antigen. Furthermore, heterologous expression in a host Pseudomonas fluorescens bacteria of an optimized polynucleotide sequence encoding a Bacillus anthracis protective antigen.

Methods and devices are provided for the detection of bacterial agents such agents as Bacillus anthracis and Clostridium botulinum with high sensitivity and selectivity. More specifically, methods and devices are based on a phosphorescence-emission detection system using chelate-stabilized lanthanides (e.g, Eu(III), Tb(III), and Sm(III)) to detect various spore-specific small organic molecules (e.g., dipicolinic acid, diaminopimelic acid, n-acetlymuramic acid, and the like). By careful selection of the chelating agent or ligand coordinated to the lanthanide, both high specificity and selectivity can be obtained. Examples of suitable and preferred sensor systems include N-(2-hydroxyethyl)ethylenediaminetriacetic acid (HEDTA) and N-(2-hydroxyethyl)iminodiacetic acid (HEIDA) combined with europium (III) and / or terbium (III). The chelate-stabilized lanthanides react with the spore-specific “target” molecules to form a characteristically phosphorescent product which can then be detected.

The invention is related to polynucleotide-based anthrax vaccines. In particular, the invention is plasmids operably encoding Bacillus anthracis antigens, in which the naturally-occurring coding regions for the B. anthracis antigens have been modified for improved translation in human or other mammalian cells through codon optimization. In certain embodiments, the coding regions are also modified so as to remove potential N-linked glycosylation sites. B. anthracis antigens which are useful in the invention include, but are not limited to protective antigen (PA), lethal factor (LF), and fragments, variants or derivatives of either of these antigens. The invention is further directed to methods to induce an immune response to B. anthracis in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized B. anthracis antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized B. anthracis antigen as described above, and further comprising adjuvants, excipients, or immune modulators.

The invention discloses a method for detecting bacillus anthracis by combining RPA with a CRISPR technology and a complete set of reagents. The invention provides a complete set of primer group for detecting the bacillus anthracis and / or screening bacillus anthracis virulent strains. The complete set of primer group contains three sets of primers specific to chromosome genes BA_5345 and plasmid virulent genes pagA and capA of the bacillus anthracis virulent strains; each set of primer is composed of an RPA primer and crRNA; the RPA primer is designed according to a target gene conserved sequence; the crRNA comprises an anchoring sequence capable of being combined with cas protein and a spacer sequence matched with an RPA primer amplification product sequence. The complete set of primer group has relatively good sensitivity and specificity for sample detection of clinical simulation samples and soil simulation samples, can effectively distinguish the bacillus anthracis virulent strainsfrom other bacteria, provides a rapid detection method for bacillus anthracis in-vitro diagnosis, and has important significance for soil environment screening of the bacillus anthracis in Chinese epidemic areas.

Method for hyper-spectral imaging and analysis of a sample of matter, for identifying and characterizing an object of interest therein. Preparing test solution or suspension of the sample, including adding thereto a spectral marker specific to object of interest, such that if object of interest is in test solution or suspension, object of interest becomes a hyper-spectrally active target which is hyper spectrally detectable and identifiable; adding to test solution or suspension a background reducing chemical, for reducing background interfering effects caused by presence of objects of non-interest in test solution or suspension, thereby increasing hyper spectral detectability of hyper spectrally active target in test solution or suspension; generating and collecting hyper-spectral image data and information of test solution or suspension; and, processing and analyzing thereof. Exemplary objects of interest are biological agents—bacteria (Bacillus anthracis), viruses, fungi, toxins, or, chemical agents—nerve agents (sarin, tabun, soman), and chemical poisons.

The invention relates to improved methods of producing and recovering sporulation-deficient B. anthracis mutant stains, and for producing and recovering recombinant B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and / or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.

The invention provides bacteriophages that infect Bacillus bacteria, including Bacillus anthracis, and compositions containing the bacteriophages. The invention also provides methods for using the bacteriophages of the invention to detect, prevent and treat infection of an organism by Bacillus bacteria. Methods and materials to decontaminate a surface or an organism that is contaminated with Bacillus bacteria or Bacillus spores are also provided.

The invention provides bacteriophages that infect Bacillus bacteria, including Bacillus anthracis, and compositions containing the bacteriophages. The invention also provides methods for using the bacteriophages of the invention to prevent and treat infection of an organism by Bacillus bacteria. Methods and materials to decontaminate a surface or an organism that is contaminated with Bacillus bacteria or Bacillus spores is also provided.

The invention discloses a method for simultaneously removing bacillus anthracis virulence megaplasmids pXO1 and pXO2. The invention provides a DNA molecule having a nucleotide sequence 1 shown in the sequence table. The invention also provides a recombinant vector, a transgenic cell line or recombinant bacteria containing the DNA molecule. The recombinant vector is prepared by inserting the DNA molecule between recognition sites HindIII and EcoRI of a shuttle plasmid. An experiment proves that according to a plasmid incompatibility principle, an incompatiple plasmid is constructed and a strain A16QT which does not contain virulence megaplasmids is obtained. The method has the characteristics of simpleness, speediness, good singularity and high safety. The method has a very important meaning for construction of a plasmid-less bacillus anthracis strain and a research on the interaction between chromosome and megaplasmids pXO1 and pXO2, provides a novel experimental means for construction of a novel vaccine, and provides a novel idea for preventing and controlling bacillus anthracis.

The present application relates generally to a method and a composition matter that provides a rapid and potent antimicrobial photodynamic inactivation (aPDI) of pathogenic bacteria that express high-affinity cell-surface hemin receptors (CSHRs) using Ga(III)-protoporphyrins IX (GaPpIX or Ga-PpIX). The invention provides an effective treatment option for infections of skin or body cavities that are accessible to visible-light irradiation, such as a handheld LED array emitting visible light (405 nm), especially for infections caused by Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus (MRSA), pathogenic staphylococci, Streptococcus mutans, S. pneumoniae, S. pyogenes, streptococci, corynebacteria, mycobacteria, and Bacillus anthracis.

The compositions and methods described herein discloses the design, synthesis and testing of compounds that act as inhibitors of DHFR. The basic scaffold of these inhibitors includes a 2,4-diaminopyrimidine ring with a propargyl linker to another substituted aryl, bicyclo or heteroaryl ring. These DHFR inhibitors are potent and selective for many different pathogenic organisms, including the DHFR enzyme from bacteria such as Bacillus anthracis and methicillin-resistant Staphylococcus aureus, fungi such as Candida glabrata, Candida albicans and Cryptococcus neoformans and protozoa such as Cryptosporidium hominis and Toxoplasma gondii. These compounds and other similar compounds are also potent against the mammalian enzyme and may be useful as anti-cancer therapeutics.

The present invention relates generally to methods and materials relating to newly characterised enzymes from Pusillimonas noertemannii, or variants thereof, capable degrading poly-γ-D-glutamic acid, for example as is present in the capsule of B. anthracis. Such depolymerases have utility as therapeutics.

The inventive subject matter relates to a competitive method for estimating the concentration in a sample of a Bacillus anthracis protein or antibody thereof selected from the group consisting of protective antigen (PA), lethal factor (LF) and edema factor (EF). The method may employ the use of Fluorescence Polarization, FLT or FRET. The competitive methods are capable of detecting a target protein within 5 minutes within the range of 0.1 to 10.0 nM. The methods provide for the rapid detection and quantitation of bacteria, bacterial antigen or antibody in culture media or broth of growing cultures of bacteria, including B. anthracis by fluorescent methods.

The invention provides a heterogeneous immunoassay for detection of antibodies and antigens based on specific antigen-antibody immune complex formation with multiple antigen-bearing conjugate components. The invention further provides means for optimizing the assay format for the detection of both low and high-affinity antibodies, and provides means for quantitative detection of both antibody and the corresponding antigen present in a sample. In preferred embodiments, the invention can be practiced to detect presence in biological fluid samples of antibodies to Bacillus anthracis related antigens.

The present invention is directed to novel pharmaceutical compositions and methods of inhibiting or blocking one or more virulence antigenic factors of multiple strains of Bacillus anthracis in an individual. Specifically, it involves the administering of an expression vector alone or in conjunction with a fusion protein. The expression vector has a transcription unit encoding a fusion protein composed of an antigenic factor of Bacillus anthracis or fragment thereof attached via a linker to the aminoterminal end of the CD40 ligand. This fusion protein has the ability to generate antibodies and / or cytotoxic T cells which inhibit or block Bacillus anthracis infection in an individual.

The present invention discloses one method of expressing anthrax bacteria gamma phage lyase and its special gene. The gene has one of the following nucleotide sequence: 1) SEQ ID No. 2 in the sequence list; 2. polynucleotide sequence coding the protein sequence of SEQ ID No. 3 in the sequence list; and 3. the nucleotide sequence capable of hybridizing with the DNA sequence limited by SEQ ID No. 2 in the sequence list under high strict condition. The optimized anthrax bacteria gamma phage lyase gene of the present invention is expressed in colibacillus system in the high expression level with expressed anthrax bacteria gamma phage lyase as high as 75 % of the all bacillus protein, has powerful anthrax bacteria schizolyzing capacity and very high specificity, and may be used in the diagnosis and prevention of anthrax and the theoretical research of anthrax treatment.

This invention discloses Bacillus anthracis gamma-phase lyase epitope, its lyase mutant and application. This invention provides the epitope of Bacillus anthracis gamma-phase lyase PlyG, and mutant lyase MPlyG. The epitope is 164th-172nd amino acid residues of lyase PlyG, and is shown in SEQ ID No.4. Mutant lyase MPlyG is derived from lyase PlyG by deleting one or more of 164th-172nd amino acid residues. Animal experiments show that compared with PlyG, MPlyG has lower antigenicity, lower immunogenicity, and similar lyase activity. Therefore, MPlyG can be used to prevent and treat charbon and manufacture corresponding drugs.

The invention relates to the technical field of biology, and specifically discloses recombinase polymerase amplification (RPA) primers and a method used for detecting bacillus anthracis. According tothe RPA primers used for detecting the bacillus anthracis, 1 pair of RPA primers are designed and synthesized on basis of a conservative sequence of a bacillus anthracis BA5345 gene; and the RPA primers are shown as SEQ ID NO. 1-2. Subjected to further optimization on primer concentration, reaction temperature and reaction time, the bacillus anthracis can be specifically detected after addition of2.0 microliters of the upstream primer and the downstream primer, of which the concentration is 10 mmol / L, into 50 microliters of a RPA reaction system and subsequent constant-temperature reaction ina water bath pot at 39 DEG C for 30 minutes; and more RPA amplification products can be obtained. Thus, the RPA detection method developed by the invention has an sensitivity which is 100 times higher than sensitivities of conventional PCR methods, as well as a positive detection rate of clinical samples of contaminated fur up to 65.71% which is significantly higher than positive detection rate of the conventional PCR methods. The RPA method established by the invention is easy to operate, fast to react, as well as true and reliable in results; and thus, the RPA method is suitable for rapid detection of the bacillus anthracis.

The invention discloses pyrazolo [1,5-a]pyridine pharmaceutical molecules used for skin ulcer nursing and a preparation method and an application thereof, which belong to the technical field of medicine synthesis. The technical scheme has the main points that the pyrazolo [1,5-a]pyridine pharmaceutical molecules have a following molecular structure shown as the specification. The invention also discloses the preparation method of the pyrazolo [1,5-a]pyridine pharmaceutical molecules and the application of the pyrazolo [1,5-a]pyridine pharmaceutical molecules in preparation of a pharmaceuticalcomposition for skin ulcer nursing. The thiazepin compounds have the advantages of keeping calm, promoting growth hormone secretion, resisting ulcer, and sterilizing; the pyrazolo [1,5-a]pyridine pharmaceutical molecules can be synthesized and an antibacterial activity test is carried, the compound has good inhibition activity on bacillus anthracis and staphylococcus due to skin ulcer, a drug ointment is prepared, a clinical nursing experiment is carried out, and the nursing effect is obvious.

The invention provides a reagent kit capable of simultaneously detecting virulent viruses and bacteria and a detecting method. The reagent kit is mainly in accordance with 4 pathogenic microorganismsof ebola viruses, Sinkiang hemorrhagic fever viruses, Brucella and anthrax bacillus. The reagent kit comprises a specific primer probe combination for detecting the ebola viruses, the Sinkiang hemorrhagic fever viruses, the Brucella and the anthrax bacillus, a micro-fluidic solid-phase PCR chip on which a specificity probe is fixed, and an RNase-resistant high-stability positive quality control product consisting of virus-like particles containing viral nucleic acid and thalli containing plasmid carrying the specificity nucleic acid. According to the reagent kit, simultaneous detection of theebola viruses, the Sinkiang hemorrhagic fever viruses, the Brucella and the anthrax bacillus can be realized, and the reagent kit has the advantages of being high in detection flux, high in sensitivity, high in specificity, good in repeatability, short in detection time, low in detection cost, low in operation technique requirements, not liable to pollute and the like, and has great application prospects in the field of quick simultaneous detection of various pathogenic microorganisms.

The invention discloses a method for expressing anthrax bacteria gamma bacteriophage lysins. The invention connects an anthrax bacteria bacteriophage gene and pMEX9K, by adopting a pichia pastoris expression system and an expression vector pMEX9K (ZL02117906.9) with intellectual property right, to construct a new expression plasmid pMEXplyG; reservoir host Pichia pastoris GS115 undergoes electrotransformation after linearization; a producing strain G6 is obtained after random selection and pressure filtering, so that the gamma bacteriophage lysins are expressed in pichia pastoris G6 supernatant, and a expression product does not contain superfluous amino acid; and the gamma bacteriophage lysins with the purity of over 95 percent are obtained after centrifuging, ultrafiltering, ion-exchange chromatography, dewatering chromatography and gel chromatography. The anthrax bacteria gamma bacteriophage lysins have cleavage activity to anthrax bacteria and fungus gemma in sprouting, and can be used to develop anthrax decontaminating agents and anthrax medicines.

The invention discloses a skin antibacterial liquid. The skin antibacterial liquid comprises the following raw materials in parts by weight, 16.13-3.22 parts of perfoliote knotweed herb, 5.33-1.06 parts of baical skullcap root, 5.38-1.09 parts of coptis root, 6.45-1.29 parts of amur corktree bark, 10.75-2.15 parts of astragalus root, 3.23-0.65 parts of divaricate saposhnikovia root, 2.15-0.43 parts of Artemisia argyi, 1.09-0.22 parts of Eucalyptus, 4.3-0.86 parts of honeysuckle, 3.23-0.65 parts of licorice and 1.09-0.22 parts of borneol. Through the mutual effect of pure traditional Chinese medicine extraction and excellent formula traditional Chinese medicinal materials, the traditional Chinese medicine composition has obvious curative effects on burns and scalds, skin ulcer, acne, urticaria, herpes zoster, eczema, pustule and the like, and also has multiple curative effects on more than thirty skin diseases such as prickly heat, Hong Kong feet, skin itch and allergic skin diseases; the traditional Chinese medicine composition can be used for preventing a patient from being repeatedly infected by bacteria and conveniently solving the skin problem of the patient, has different degrees of bacteriostatic action on staphylococcus aureus, diplococcus pneumoniae, streptococcus deep haemolyticus, corynebacterium diphtheriae, pseudomonas aeruginosa and bacillus anthracis, effectivelyimproves the effects of sterilization, bacteriostasis, inflammation resistance and allergy resistance, improves the treatment effect and is convenient to use.

Disclosed is a protein comprising a cytolethal distending toxin subunit B (CdtB) conjugated or fused to a Bacillus anthracis toxin lethal factor (LF) or a functional portion of LF. Related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of treating or preventing cancer, and methods of inhibiting the growth of a target cell are also disclosed.